Such a theranostic approach has only been clinically approved so far for neuroendocrine tumor therapy and is in late-stage clinical trials for prostate cancer, using agents targeting the SSTR2 [427] and the Prostate Specific Membrane Antigen (PSMA) [428], respectively. This evidence concerns the gene FOLH1 and prostate carcinoma.